Linksys Brings Best in Class WiFi Performance to the Home with New Series of Affordable WiFi 6 Mesh Solutions
24.5.2022 18:00:00 EEST | Business Wire | Press release
Linksys, a global leader in home and business WiFi networking solutions, today announced two new WiFi 6 mesh systems designed to deliver peak wireless performance for all at-home needs including remote working, streaming content, multi-user gaming and more. The Linksys Hydra 6 and Linksys Atlas 6 are Linksys’ newest entry-level dual-band products in the company's family of WiFi 6 mesh systems and come at the most affordable prices to date for the brand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005310/en/
Linksys Atlas 6 (Photo: Business Wire)
“There is an increased need for wireless connectivity that can handle the influx of devices on home networks, and deliver reliable, secure and private connections,” said Alan Cohen, VP of Marketing and Head of Product at Linksys. “Our mission is to connect everyone securely and through the launch of these systems, we provide our customers with two new options for fast speed, coverage, and connectivity at an affordable price point.”
Linksys Atlas 6 – Our Most Affordable WiFi 6 Mesh System to Date
The Linksys Atlas 6 is the newest whole-home mesh system in Linksys’ portfolio of products. Speed and performance at an affordable price, the Linksys Atlas 6 is ideal for hybrid work, online gaming, 4K UHD streaming, and more. The dual-band router works best with internet service plans up to a gigabit. Each Node has three 1Gbps Ethernet LAN ports for connecting wired devices to wireless networks and provides access to 160MHz channels for superfast wireless connections.
The Linksys Atlas 6 is available in three configurations. The 1-pack supports up to 25 devices and covers ~2,000 square feet, the 2-pack supports up to 50 devices and covers ~4,000 square feet, and the 3-pack supports up to 75 devices and up to ~6,000 square feet.
Linksys Hydra 6 – Dramatically Faster, Robust, and Reliable Connectivity
The Linksys Hydra 6 delivers high-speed wireless data for up to 25 devices over 2,000 square feet. The Linksys Hydra 6 WiFi 6 dual-band mesh router delivers dramatically faster, robust, and reliable wireless connections. Ideal for super smooth 4K UHD streaming, video conferencing, online gaming, and more. The router works best with internet service plans up to a gigabit. It provides 160 MHz channels for superfast wireless connections and has four 1 GbE Ethernet ports to connect wired devices such as gaming devices, television, DVR, and more to the wireless network.
Additional Features and Benefits for the Linksys Atlas 6 and Hydra 6
- Fast to set up. Easy to manage. – The Linksys App makes it simple to set up your WiFi network and you can control and monitor your WiFi from anywhere.
- Linksys Intelligent Mesh™ Technology – Dynamically optimize speeds and maximize the use of all bands to reduce congestion, latency and buffering.
- Security and privacy you can trust – Protect your home with automatic software updates so your network is always secure and up to date. Parental controls and separate guest networks keep devices safe.
- Peace of mind – Linksys products pass 25 quality tests, are backed by a 3-year warranty, and have 24/7 tech support.
- Grow as needed – When your family, home and needs grow, your WiFi should grow with you. Add more nodes to expand coverage for stronger connection and to handle more devices as needed.
- Robust. Stable. Reliable. – Built with the Qualcomm® Immersive Home 214 Platform users can expect great connectivity throughout the home.
Availability and Imagery
The Linksys Hydra 6 will be available beginning early summer in the US for MSRP $179.99 on Linksys.com and in select retailers; global availability to follow in the second half of 2022.
The Linksys Atlas 6 will be available beginning early summer in the US for MSRP $149.99 (1-pack), $279.99 (2-pack), and $349.99 (3-pack) on Linksys.com; global availability to follow in the second half of 2022.
Images of the Atlas 6 and Hydra 6 can be found here.
About Linksys
At Linksys, we strive to build the world’s most reliable, innovative, future-ready wireless technologies that can securely connect every person and everything, effortlessly. Founded in 1988, Linksys has since established itself as a premier networking brand. Today, Linksys hardware products, software, and services are sold in 64 countries worldwide, ranging from home routers and mesh systems to business access points and switches. Recently, Linksys expanded into education and enterprise through its partnership with Fortinet, the leader in enterprise-grade security. Linksys. For every connection.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm Immersive Home 214 Platform is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005310/en/
Contact information
Asees Singh
Sr. Global Communications Manager
Comms@linksys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
